UnitedHealth Group stock faces a Q3 earnings test as costs matter

UnitedHealth Group (ISIN US91324P1021) was trading at USD 374.98 on the NYSE on October 6, 2026, at 11:57 a.m. ET, down 0.95 percent from the prior close. The next test is scheduled for October 13, when the company will publish third-quarter results before the market opens.

October 13 sets the next test

According to UnitedHealth Group in its release dated September 15, 2026, third-quarter financial results will arrive on October 13 before the market opens, followed by an 8:00 a.m. ET conference call. That date gives investors a defined checkpoint for the insurer's cost trend and earnings recovery.

Q2 earnings raised the bar

MarketBeat reported on October 6, 2026, that UnitedHealth delivered adjusted EPS of USD 6.38 in the second quarter of 2026, versus USD 4.94 consensus and USD 4.08 in the prior-year quarter. Revenue reached USD 112.03 billion, up 0.4 percent year over year and above the USD 110.81 billion consensus.

The second-quarter comparison was driven more by profitability than by sales growth. UnitedHealth's adjusted EPS rose 56.4 percent from USD 4.08, while revenue increased only 0.4 percent, leaving medical costs as the central variable for the October report.

Medical costs remain decisive

In the Q2 earnings call, Fortune reported that the medical care ratio improved to 86.7 percent in Q2 2026 from 89.4 percent in Q2 2025. Management also set full-year adjusted EPS guidance at USD 19.50-20.00 and projected a 2026 medical care ratio of 88.1 percent plus or minus 25 basis points.

The coverage strategy adds a second operating test. Yahoo Finance reported on October 5, 2026, that UnitedHealthcare plans to provide 66 percent of members access to both HMO and PPO plans in 2027, compared with 70 percent in 2026. The narrower mix reflects an effort to prioritize plan economics while medical utilization remains elevated.

Consensus stays above the market price

UnitedHealth's USD 374.98 price on October 6, 2026, stood 18.8 percent below the 52-week high of USD 461.62 and above the 52-week low of USD 255.97. The market capitalization was USD 340.5 billion, giving the earnings release a large valuation base against which to measure any change in margins.

According to MarketBeat on October 6, 2026, 20 analysts rated the stock Buy and eight rated it Hold, producing a Moderate Buy consensus and an average price target of USD 465.75. That target lies 24.2 percent above the October 6 price, while the upcoming report must show whether improved medical costs can support the recovery implied by the consensus.

NYSE price before the results

UnitedHealth Group stock was last trading at USD 374.98 on the NYSE on October 6, 2026, at 11:57 a.m. ET, with a session range of USD 374.44 to USD 380.41 and volume of 1,341,492 shares.

Upcoming dates for UnitedHealth Group stock

• October 13, 2026: Third-quarter 2026 results before the market opens

More news and analyses on UnitedHealth Group stock